Adaptive Decision Making Based on Interval-Censored Data in a Clinical Trial to Optimize Rapid Treatment of Stroke - Interval-Censored-Time-to-Event Data: Methods and Applications - page 341

https://biostatistics.mdanderson.org/SoftwareDownload .

Acknowledgments

This research was partially supported by NCI grant RO1-CA-83932.

Bibliography

Bekele, B. N. and Shen, Y. (2005). A Bayesian approach to jointly mod-

eling toxicity and biomarker expression in a phase I/II dose-finding trial.
Biometrics 60, 343{354.

Berger, J. O. (1985). Statistical Decision Theory and Bayesian Analysis, 2nd

edition. New York: Springer-Verlag.

Braun, T. M. (2002). The bivariate continual reassessment method: Extend-

ing the CRM to phase I trials of two competing outcomes. Contemporary

Clinical Trials 23, 240{256.

Braun, T. M., Thall, P. F., Nguyen, H., and de Lima, M. (2007). Simultane-

ously optimizing dose and schedule of a new cytotoxic agent. Clinical Trials

4, 113{124.

deVeber, G., MacGregor, D., Curtis, R., and Mayank, S. (2000). Neurologic

outcome in survivors of childhood arterial ischemic stroke and sinovenous

thrombosis. Journal of Childhood Neurology 15(5), 316{324.

Houede, N., Thall, P. F., Nguyen, H., Paoletti, X., and Kramar, A. (2010).